


NEW ORLEANS, Jan. 28, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 9, 2026 to file lead plaintiff applications in a securities class action lawsuit against Integer Holdings Corporation (“Integer” or the “Company”) (NYSE: ITGR), if they purchased or otherwise acquired the Company’s shares between July 25, 2024 and October 22, 2025, inclusive (the “Class Period”). This action is pending in the United States District...
Integer Holdings has, in recent months, cut its 2025 sales guidance and disclosed slower-than-expected adoption of several electrophysiology and neuromodulation products, triggering multiple securities class action lawsuits that allege it overstated demand and its competitive position. Beyond the legal overhang, the controversy spotlights questions about the company’s visibility into new-product uptake and the reliability of prior growth messaging in a key cardiovascular niche. With this...
Key PointsInteger CEO Khales Payman bought 3,127 shares of the companys stock on Oct. 30, 2025.Mr. Payman purchased his companys stock on the day shares hit a 52-week low of $62.These 10 stocks could mint the next wave of millionaires › Khales Payman, President and CEO of Integer Holdings Corporation (NYSE:ITGR), acquired 3,127 shares in his company in an open-market buy on October 30, 2025, according to an SEC Form 4 filing.Transaction summaryMetricValueShares traded3,127Transaction value~$20...
Integer Holdings posts strong Q3 results with earnings and revenue beat, but shares plunge on a softer 2026 growth outlook.
Shares of medical technology company Integer Holdings (NYSE:ITGR) fell 31.4% in the afternoon session after the company reported third quarter earnings which revealed a significant reduction in its full-year profit forecast.
ITGR posts strong second-quarter revenue growth, but EPS misses estimate despite solid segment momentum.
Integer Holdings fourth-quarter results reflect robust sales from the majority of the product lines, along with continued product adoption.
ITGR shares gain on the back of growth in the Medical segment. However, dependence on third-party suppliers is concerning.
ITGR shares gain on the back of growth in the Medical segment. However, fluctuations in the oil and energy market are concerning.
ITGRs third-quarter results reflect solid Medical sales and margin expansion amid the divestiture of its Electrochem business.
Integer Holdings (ITGR) shares gain on the back of growth in the Medical segment. However, fluctuations in raw material prices and the oil and energy market are concerning.
Integer Holdings announces to divest its Electrochem business to Ultralife for $50 million in cash.
Integer Holdings announces the completion of its Irish facility expansions in Galway and New Ross to support growth.
Integer Holdings (ITGR) shares gain on the back of growth in the Medical segment. However, fluctuations in raw material prices and the oil and energy market are concerning.
Integer Holdings (ITGR) second-quarter results reflect robust Medical Sales, along with strength in all the product lines.
Integer Holdings (ITGR) research and product development activities raise optimism about the stock.
Integer Holdings (ITGR) shares soar on the back of growth in the Medical segment. However, fluctuations in raw material prices and the oil and energy market are concerning.
Integer Holdings (ITGR) research and product development activities raise optimism about the stock.
Integer Holdings (ITGR) first-quarter results reflect robust Medical Sales, along with strength in all the product lines.
Integer Holdings shares upgraded on PFA market potential
Investors are optimistic about Integer Holdings (ITGR) research and product development activities.
Integer Holdings (ITGR) research and product development activities raise optimism about the stock.
Investors are optimistic about Integer Holdings (ITGR) research and product development activities.